Abstract
Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Current Drug Therapy
Title: Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Volume: 1 Issue: 2
Author(s): Karim Bendjelid
Affiliation:
Keywords: Circulatory shock, cardiomyopathy, cardiac depression, anti inflammatory
Abstract: Beta-blockers, previously considered contraindicated in heart failure are today amongst the most important drugs in heart failure. They improve survival and retard the need for cardiac transplantation. Since most clinical trials demonstrating the benefits of beta-blockers have been done in patients with mild to moderate heart failure, the use of these agents in patients with advanced heart failure remains contraindicated. In this brief review, the author theorizes that due to their immunomodulatory effects, beta-blockers may also play a helpful role in patients presenting cardiogenic shock related to septic shock. However, intensivists should keep in mind that no clinical data are available so far on the role of beta-blockers in septic cardiac shock. Thereby, because the use of beta-blockers in this setting is not established, nor recommended, it should only be applied under controlled trial conditions.
Export Options
About this article
Cite this article as:
Bendjelid Karim, Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930941
DOI https://dx.doi.org/10.2174/157488506776930941 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lower Financial Status and Adherence to Medication Determines 10-Year (2004-2014) All-Cause Mortality and Risk for Acute Coronary Syndrome Incidence Among Cardiac Patients: the GREECS Study
Current Vascular Pharmacology Heptahelical Receptors for Lysolipids in Lymphocytes as Targets for Therapeutic Intervention
Drug Design Reviews - Online (Discontinued) Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases
Current Vascular Pharmacology The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Theoretical Possibilities for the Development of Novel Antiarrhythmic Drugs
Current Medicinal Chemistry Application of Erythropoietin in Chronic Heart Failure Treatment
Mini-Reviews in Medicinal Chemistry Histone Deacetylase Inhibitors: Recent Insights from Basic to Clinical Knowledge & Patenting of Anti-Cancer Actions
Recent Patents on Anti-Cancer Drug Discovery Management of Spasticity in Progressive Multiple Sclerosis: Efficacy of Repeated Intrathecal Triamcinolone Acetonide Administration
Current Pharmaceutical Design Eotaxins and CCR3 Receptor in Inflammatory and Allergic Skin Diseases: Therapeutical Implications
Current Drug Targets - Inflammation & Allergy Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Nanomedicine as a Strategy for Natural Compound Delivery to Prevent and Treat Cancers
Current Pharmaceutical Design Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Current Pharmaceutical Design New Developments in Anthracycline-Induced Cardiotoxicity
Current Medicinal Chemistry Fundamentals of Light Chain Cardiac Amyloidosis: A Focused Review
Cardiovascular & Hematological Disorders-Drug Targets An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design